📊 XFOR Key Takeaways
Is X4 Pharmaceuticals, Inc (XFOR) a Good Investment?
X4 Pharmaceuticals is experiencing critical fundamental deterioration with revenue collapsing 81.5% YoY to $6.5M while operating losses widened to $86.9M, indicating severe commercial or pipeline execution failure. Despite a $217M cash cushion providing approximately 2.5 years of runway at current burn rates, the company's inability to generate meaningful revenue combined with persistent operating losses of -1336.7% margin demonstrates an unsustainable business model requiring near-term transformative catalysts.
Why Buy X4 Pharmaceuticals, Inc Stock? XFOR Key Strengths
- Strong cash position of $217M with low debt-to-equity of 0.40x providing operational runway
- Excellent short-term liquidity with current ratio of 10.16x enabling near-term survival
- Moderate leverage with manageable long-term debt of $75M relative to equity base
XFOR Stock Risks: X4 Pharmaceuticals, Inc Investment Risks
- Catastrophic 81.5% revenue decline YoY indicating loss of major product/customer or commercial failure
- Severe cash burn of $85.6M annually with negative operating cash flow outpacing minimal revenue
- Deteriorating profitability with net losses worsening 111.5% YoY and negative ROE of -42.5% destroying shareholder value
- Negative interest coverage of -13.4x indicating inability to service debt from operations
- Biotech execution risk: clinical failure, regulatory setback, or failed commercialization strategy apparent from revenue collapse
Key Metrics to Watch
- Quarterly revenue trajectory and pipeline product launch milestones
- Operating cash burn rate and months of cash runway remaining
- Clinical trial outcomes and regulatory approval status for key programs
X4 Pharmaceuticals, Inc (XFOR) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 10.16x current ratio provides a solid financial cushion.
XFOR Profit Margin, ROE & Profitability Analysis
XFOR vs Healthcare Sector: How X4 Pharmaceuticals, Inc Compares
How X4 Pharmaceuticals, Inc compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is X4 Pharmaceuticals, Inc Stock Overvalued? XFOR Valuation Analysis 2026
Based on fundamental analysis, X4 Pharmaceuticals, Inc shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
X4 Pharmaceuticals, Inc Balance Sheet: XFOR Debt, Cash & Liquidity
XFOR Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: X4 Pharmaceuticals, Inc's revenue has grown significantly by 1,070% over the 5-year period, indicating strong business expansion. The most recent EPS of $-17.07 indicates the company is currently unprofitable.
XFOR Revenue Growth, EPS Growth & YoY Performance
XFOR Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $560.0K | $282.0K | $0.35 |
| Q2 2025 | $563.0K | $282.0K | $-3.47 |
| Q1 2025 | N/A | $282.0K | $0.04 |
| Q2 2024 | $700.0K | -$24.0M | $0.19 |
| Q3 2021 | N/A | -$11.1M | N/A |
| Q2 2021 | N/A | -$11.1M | N/A |
| Q1 2021 | N/A | -$11.1M | N/A |
| Q3 2020 | N/A | -$10.9M | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
X4 Pharmaceuticals, Inc Dividends, Buybacks & Capital Allocation
XFOR SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for X4 Pharmaceuticals, Inc (CIK: 0001501697)
📋 Recent SEC Filings
❓ Frequently Asked Questions about XFOR
What is the AI rating for XFOR?
X4 Pharmaceuticals, Inc (XFOR) has an AI rating of STRONG SELL with 85% confidence, based on fundamental analysis of SEC EDGAR filings.
What are XFOR's key strengths?
Claude: Strong cash position of $217M with low debt-to-equity of 0.40x providing operational runway. Excellent short-term liquidity with current ratio of 10.16x enabling near-term survival.
What are the risks of investing in XFOR?
Claude: Catastrophic 81.5% revenue decline YoY indicating loss of major product/customer or commercial failure. Severe cash burn of $85.6M annually with negative operating cash flow outpacing minimal revenue.
What is XFOR's revenue and growth?
X4 Pharmaceuticals, Inc reported revenue of $6.5M.
Does XFOR pay dividends?
X4 Pharmaceuticals, Inc does not currently pay dividends.
Where can I find XFOR SEC filings?
Official SEC filings for X4 Pharmaceuticals, Inc (CIK: 0001501697) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is XFOR's EPS?
X4 Pharmaceuticals, Inc has a diluted EPS of $-1.87.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is XFOR a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, X4 Pharmaceuticals, Inc has a STRONG SELL rating with 85% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is XFOR stock overvalued or undervalued?
Valuation metrics for XFOR: ROE of -42.5% (sector avg: 15%), net margin of -1,218.4% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy XFOR stock in 2026?
Our dual AI analysis gives X4 Pharmaceuticals, Inc a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is XFOR's free cash flow?
X4 Pharmaceuticals, Inc's operating cash flow is $-85.6M, with capital expenditures of $0.0. FCF margin is -1,317.2%.
How does XFOR compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -1,218.4% (avg: 12%), ROE -42.5% (avg: 15%), current ratio 10.16 (avg: 2).